Article
Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
Clinical pharmacology in drug development - 1 Apr 2022
Fan Bin, Chen Yue, Yin Feng, Hua Lei, Almon Caroline, Nabhan Salah, Cooper Michael, Yang Hua, Hossain Mohammad
Abstract excerpt
Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) proteins catalyze production of the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib and enasidenib are oral inhibitors of mIDH1 and mIDH2, respectively. An open-label phase 1 study is evaluating the safety and efficacy of ivosidenib or enasidenib combined with intensive induction and consolidation chemotherapy in adult patients with newly diagnosed mIDH1/2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.